Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors

Summary by mykxlg.com
Macau SAR, China regulator grants approval for ANKTIVA® (nogapendekin alfa inbakicept-pmln) in patients with
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.Cross Cancel Icon

3 Articles

stocktitan.netstocktitan.net
+2 Reposted by 2 other sources

ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

stocktitan.net broke the news in on Friday, March 20, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

Macau icon

Macau

China icon

China

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal